Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

789
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
789
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.0K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

821
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
821
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

1.3K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.3K
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

953
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
953
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

666
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
666

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amylase and lipase in alcohol-induced acute pancreatitis: Time to rethink diagnostic thresholds?

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2026
Same author

European Interdisciplinary Guidelines on Pain Management in Acute Pancreatitis: UEG, EPC, EDS, ESDO, EAGEN, ESPGHAN, ESGAR, and ESPCG Evidence-Based Recommendations.

United European gastroenterology journal·2026
Same author

Fulminant Hepatic Failure Following Initiation of Abiraterone in Metastatic Prostate Cancer: A Fatal Adverse Drug Reaction.

Case reports in hepatology·2026
Same author

Digitally supported, patient-initiated care: Maintaining control of inflammatory bowel diseases while achieving high patient satisfaction.

International journal of medical informatics·2026
Same author

Recent advances in our understanding of the gut microbiome: an analysis from the Gut Microbiota for Health Expert Panel of the British Society of Gastroenterology.

Gut·2026
Same author

VIGA (VIrtual GAster): An integrated analysis platform for quantitative assessments of gastric geometry and motility using MRI.

Medical physics·2026

Related Experiment Video

Updated: Mar 9, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
03:50

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

3.1K

Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline.

Stefan Müller-Lissner1, Gabrio Bassotti2, Benoit Coffin3

  • 1Department of Internal Medicine, Park-Klinik Weissensee, Berlin, Germany.

Pain Medicine (Malden, Mass.)
|December 31, 2016
PubMed
Summary

This study provides evidence-based guidelines for managing opioid-induced bowel dysfunction (OIBD). New treatment approaches are emerging, but clinical best practice guidelines for OIBD are still needed.

Keywords:
ConstipationLaxativesOpioid AntagonistsOpioidsPAMORAs

More Related Videos

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

1.1K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.9K

Related Experiment Videos

Last Updated: Mar 9, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
03:50

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

3.1K
Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

1.1K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.9K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Evidence-based Medicine

Background:

  • Opioid-induced constipation is a common adverse effect of opioid therapy.
  • Opioid effects extend beyond the colon, impacting the entire gastrointestinal tract, leading to opioid-induced bowel dysfunction (OIBD).
  • Increasing opioid prescriptions correlate with a rising incidence of OIBD.

Purpose of the Study:

  • To develop timely, evidence-based guidelines for the clinical management of opioid-induced bowel dysfunction.
  • To provide guidance on best practices for patients experiencing OIBD.

Main Methods:

  • Comprehensive literature search across major databases (Medline, EMBASE, Cochrane).
  • Inclusion/exclusion criteria applied to identify relevant studies.
  • Statements formulated, justified, and graded using the Strength of Recommendation Taxonomy (SORT) system.

Main Results:

  • 33 relevant citations identified from over 10,000 initial studies.
  • Review of OIBD definitions, prevalence, and mechanisms.
  • Development of a treatment algorithm and patient management statements for OIBD.

Conclusions:

  • Despite increased understanding of OIBD pathophysiology and new treatments, clinical guidelines remain scarce.
  • Current knowledge on managing upper gastrointestinal effects of opioids is limited.
  • Recommendations for clinical best practice in OIBD management are proposed based on available evidence.